Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,654 across all filing types
Latest filing 2026-01-07 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
关于SAL0145药品临床试验申请获得受理的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding the acceptance of a clinical trial application for a new drug (SAL0145). It includes details about the drug, regulatory acceptance, and future steps. There is no financial data, no mention of financial results, no management discussion, no shareholder voting, no capital changes, or other financial or governance topics. The document is an official announcement related to regulatory approval and clinical trial progress, not a financial report or meeting material. It fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2026-01-07 Chinese
2025年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a resolution announcement for the "2025 First Extraordinary General Meeting of Shareholders" of Shenzhen Salubris Pharmaceuticals Co., Ltd. It details the meeting's convening, attendance, voting results on various proposals, and legal opinions confirming the meeting's compliance with laws and regulations. The content focuses on the official results of shareholder votes at a general meeting, including detailed voting statistics and resolutions passed. There is no indication that this is a full annual report, interim report, or other financial report. The document is not a proxy solicitation or a presentation but an official announcement of voting results. Therefore, the document fits the category of "Declaration of Voting Results & Voting Rights Announcements" (DVA). The document length is about 4942 characters, which is sufficient for a detailed voting result announcement. Confidence is high due to the clear match with the DVA category definition.
2025-12-25 Chinese
北京市金杜（深圳）律师事务所关于深圳信立泰药业股份有限公司2025年第一次临时股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the convening, procedures, attendance, and voting results of the 2025 first extraordinary general meeting (临时股东大会) of Shenzhen Salubris Pharmaceuticals Co., Ltd. It details the legal compliance of the meeting's call, attendance, and voting process, including verification of shareholder qualifications and vote counts. The document does not contain financial statements or management discussion of financial results, nor is it a report of financial performance. It is a legal opinion related to a shareholders' meeting and the voting results of that meeting. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially reports the voting results of a shareholders' meeting. The document length is sufficient and it is not merely an announcement of a report publication. Therefore, the correct classification is DVA with high confidence.
2025-12-25 Chinese
关于SAL0137获得临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (829 characters) from Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding the receipt of a clinical trial approval notice for a drug candidate SAL0137. It includes no financial data, no detailed report, and no regulatory form references. It is an announcement of a regulatory approval event related to clinical trials, not a financial report or management information. The document is not a report itself but a notification of an event. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-12-19 Chinese
关于筹划发行H股股票并在香港联合交易所有限公司上市的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement (708 characters) regarding the company's plan to issue H shares and list on the Hong Kong Stock Exchange. It states that the plan is still under discussion and subject to approvals and regulatory filings. There is no detailed financial data or report content, only a notification of the intention and regulatory process. The document is not a full report but a regulatory announcement about a capital market activity. Therefore, it fits best under Capital/Financing Update (CAP).
2025-12-11 Chinese
董事薪酬管理制度（2025年12月）
Remuneration Information Classification · 95% confidence The document is titled '董事薪酬管理制度' which translates to 'Director Remuneration Management System'. It details the principles, management structure, salary standards, and adjustment mechanisms for director compensation. It references governance codes and company bylaws, and it is a policy document rather than a report of compensation paid or a proxy statement. It does not contain financial results, voting results, or executive compensation tables typically found in DEF 14A filings. It is a governance-related document outlining internal rules and practices regarding director remuneration. Therefore, it fits best under the category of Remuneration Information (DEF 14A), which covers reports detailing compensation for top executives and directors, including policies and management systems related to remuneration.
2025-12-09 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.